Julie D Saba

University of California, San Francisco

NIH Rank #6968
  • R01 Holder
  • Early Career
  • Diverse Portfolio

NIH Funding · FY2024

Total Funding
$1.7M
Fiscal year 2024
Grants Awarded
3
Active NIH grants
National Rank
#6,968
Among 57,894 PIs
First NIH Award
2024
Year of first funding

Funding & rank history

NIH funding totals and national rank by fiscal year.

Single fiscal year on record (FY2024): $1.7M across 3 grants · National rank #6968.

Top grants by award amount

Julie D Saba's NIH grant portfolio, ranked by award amount.

  • 1R01HD113778-01R01
    Characterizing the natural history of sphingosine phosphate lyase insufficiency syndrome (SPLIS): a fundamental step in the development of a targeted cure for this novel atypical sphingolipidosis
    $693.5K
    award amount
  • 1R61HL171786-01R61
    Adeno-associated virus-mediated SGPL1 gene therapy as a first-in-class treatment for idiopathic pulmonary fibrosis that acts by reducing sphingosine-1-phosphate and downstream profibrotic signaling
    $565.3K
    award amount
  • 1R21TR005157-01R21
    Proof-of-concept for the use of enzyme replacement therapy as a lifesaving treatment for sphingosine phosphate lyase insufficiency syndrome
    $463.2K
    award amount

Affiliation

Institutions that have administered grants for Julie D Saba.

Affiliated with University of California, San Francisco (CA).

Career milestones

Key NIH funding milestones over time.

  1. 2024
    First NIH Award
    University of California, San Francisco
  2. 2024
    $500K Cumulative Funding
  3. 2024
    $1M Cumulative Funding
  4. 2024
    Entered Top 50% Nationally
    Ranked #6968